Safety and reactogenicity study of GlaxoSmithKline (GSK) Biologicals’ investigational respiratory syncytial virus (RSV) vaccine (GSK3003891A) in healthy women

Mise à jour : Il y a 4 ans
Référence : EUCTR2015-005742-58

Femme Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To evaluate the reactogenicity and safety of a single dose of the investigational RSV vaccine in healthy non-pregnant women during the study period.


Critère d'inclusion

  • Healthy volunteers (prevention of severe RSV disease in infants by transfer of maternal antibodies following active single dose immunisation of pregnant women)

Liens